China Bladder Cancer Market

China Bladder Cancer Market Size, Share & Trends Analysis Report by Cancer Type (Transitional Cell Bladder Cancer/ Urothelial Carcinoma, Squamous Cell Bladder Cancer, Adenocarcinoma, and Other), by Diagnosis (Cystoscopy, Biopsy, Urinalysis, Urine Cytology, Intravenous Pyelogram (IVP), and Others), and by Treatment (Chemotherapy, Immunotherapy, Radiation Therapy, Surgery, and Other) and Forecast, 2020-2026
    Update Available - Forecast 2024-2030   

Published: Jul 2022 | Report Code: OMR2022182 | Category : Pharmaceuticals | Delivery Format: /

China bladder cancer market is estimated to grow modestly at a CAGR of around 10.1% during the forecast period. The country has a strong healthcare industry and is continuously developing medical facilities and research centers to improve the industry further. Bladder cancer is one of the major cancers diagnosed in the elderly population of the country. The growing prevalence of bladder cancer in the country is attributed to growth in the aging population and a rapid increase in the number of smokers. Cancer is one of the leading causes of mortality in China. According to WHO, China has reported a total of 82,270 new cases of bladder cancer in 2018 out of which 38,208 cases resulted in mortality. As per the organization, China accounts for 222,292 bladder cancer patients in the last 5 years. Due to increasing industrialization in the country, harmful chemicals are being ejected into the atmosphere and chemical exposure is one of the major causes of bladder cancer. Therefore, with rapid industrialization in the country, China is estimated to contribute substantially to the global bladder cancer market during the forecast period.

China bladder cancer market is segmented into cancer type, diagnosis, and treatment. Based on cancer type, the market is segmented into transitional cell bladder cancer/ urothelial carcinoma, squamous cell bladder cancer, adenocarcinoma, and other rare types (sarcomas, carcinoma in situ). Based on the diagnosis, the market is segmented into cystoscopy, biopsy, urinalysis, urine cytology, intravenous pyelogram (IVP), and others. Based on treatment, the market is segmented into chemotherapy, immunotherapy, radiation therapy, surgery, and other treatment which include targeted therapy.  

The companies which are contributing to the growth of China bladder cancer market include AstraZeneca PLC, Bristol-Myers Squibb, Co., Eli Lilly & Co., GlaxoSmithKline PLC, and Pfizer, Inc. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market. 

Research Methodology

The market study of the China bladder cancer market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, various services offered by the players, and market opportunity. The report will serve as a source for 360-degree analysis of the market delivering insights for making better business decisions.

Market Segmentation

  1. China Bladder Cancer Market Research and Analysis by Cancer Type
  2. China Bladder Cancer Market Research and Analysis by Diagnosis
  3. China Bladder Cancer Market Research and Analysis by Treatment

The Report Covers

  • Comprehensive research methodology of the China bladder cancer market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the China bladder cancer market.
  • Insights about market determinants which are stimulating the China bladder cancer market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

1. Report Summary

1.1. Research Methods and Tools

1.2. Market Breakdown

1.2.1. By Segments

2. Market Overview and Insights

2.1. Scope of the Report

2.2. Analyst Insight & Current Market Trends

2.2.1. Key Findings

2.2.2. Recommendations

2.2.3. Conclusion

2.3. Rules & Regulations

3. Competitive Landscape

3.1. Company Share Analysis 

3.2. Key Strategy Analysis

3.3. Key Company Analysis

3.3.1. Overview

3.3.2. Financial Analysis

3.3.3. SWOT Analysis

3.3.4. Recent Developments

4. Market Determinants 

4.1. Motivators

4.2. Restraints

4.3. Opportunities 

5. Market Segmentation

5.1. China Bladder Cancer Market by Cancer Type

5.1.1. Transitional Cell Bladder Cancer/ Urothelial Carcinoma

5.1.2. Squamous Cell Bladder Cancer

5.1.3. Adenocarcinoma

5.1.4. Others (Sarcomas, Carcinoma in Situ)

5.2. China Bladder Cancer Market by Diagnosis

5.2.1. Cystoscopy

5.2.2. Biopsy

5.2.3. Urinalysis

5.2.4. Urine Cytology

5.2.5. Intravenous Pyelogram (IVP)

5.2.6. Others (Biomarkers)

5.3. China Bladder Cancer Market by Treatment

5.3.1. Surgery

5.3.2. Chemotherapy

5.3.3. Immunotherapy

5.3.4. Radiation Therapy

5.3.5. Others (Targeted Therapy)

6. Company Profiles

6.1. Astellas Pharma Inc.

6.2. AstraZeneca PLC

6.3. Bayer AG

6.4. Bristol-Myers Squibb Co.

6.5. Eli Lilly and Co.

6.6. F. Hoffmann-La Roche AG

6.7. GlaxoSmithKline Plc

6.8. Johnson & Johnson Services, Inc.

6.9. Merck KGaA

6.10. Pfizer Inc.

6.11. Sysmex Corp.

1. CHINA BLADDER CANCER MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2019-2026 ($ MILLION)

2. CHINA BLADDER CANCER MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2019-2026 ($ MILLION)

3. CHINA BLADDER CANCER MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2019-2026 ($ MILLION)

1. CHINA BLADDER CANCER MARKET SHARE BY CANCER TYPE, 2019 VS 2026 (%)

2. CHINA BLADDER CANCER MARKET SHARE BY DIAGNOSIS, 2019 VS 2026 (%)

3. CHINA BLADDER CANCER MARKET SHARE BY TREATMENT, 2019 VS 2026 (%)